Huntington's disease (HD) is a fatal, autosomal dominant, neurodegenerative disorder caused by a glutamine-coding CAG expansion within exon 1 of the huntingtin gene. Although the genetic mutation associated with the disease has been identified, the molecular and cellular basis of HD is not yet understood and successful treatment for this disease remains elusive. Basic research and clinical studies indicate that mitochondrial dysfunction plays an important role in the pathogenesis of HD. Mitochondria are organized in a highly dynamic tubular network that is continuously reshaped by opposing processes of fusion and fission. Dynamin-related protein 1 (Drp1) is a large GTPase and a key protein governing mitochondrial fission. Recent studies have highlighted the causal role of Drp1-mediated excessive mitochondrial fission in neuronal death in HD cell culture models. However, how Drp1 hyperactivation mediates mitochondrial damage and neurodegeneration in HD and whether pharmacological inhibition of Drp1 activation is sufficient to reduce mutant Htt (mtHtt)-induced neurotoxicity and neurodegeneration are not known. Our recent work showed that Drp1 is translocated to the mitochondria and hyper-activated in both HD cell cultures and in vivo in the HD R6/2 transgenic mouse brain. Importantly, using a novel and selective peptide inhibitor of Drp1, P110, recently developed in our group, we found that inhibition of Drp1-dependent mitochondrial impairment corrected mitochondrial dysfunction and neuronal cell death in HD cell cultures, and reduced behavioral deficits and loss of striatal neurons in HD R6/2 transgenic mice. Moreover, treatment with P110 corrected mitochondrial morphology and reduced neurite loss and cell death in GABAergic striatal neurons derived from HD patient- induced pluripotent stem cells (HD-iPS cells). Further, using unbiased proteomic analysis, we recently profiled the interactome of Drp1 in neuronal cultures derived from HD patient-iPS cells. Our preliminary studies identified two mechanistically distinct candidate proteins (ATADA3, a member of mitochondrial AAA-ATPase family, and MAPK1, a serine/threonine kinase) that are involved in Drp1-mediated neuronal damage. These lines of evidence indicate that Drp1 hyperactivation is a predominant cause of neurodegeneration in HD. Thus, we hypothesize that inhibition of Drp1-mediated mitochondrial damage is a novel approach for reducing neuropathology in HD models in vitro and in vivo. Using biochemical, imaging, bio-energetic, proteomic and pharmacological approaches ranging from animals to patient neurons, our goal in this application is to unravel the complexity of Drp1-mediated mitochondrial dysfunction in neurodegeneration in both mechanistic and therapeutic detail. The proposed study will produce novel information on the role of Drp1-mediated mitochondrial fission in the pathogenesis of HD and provide a useful model system in which to study mitochondrial pathology in striatal neurons. We will also generate pharmacological tools to inhibit HD pathogenesis as a first step towards the development of novel therapeutics for HD.

Public Health Relevance

Huntington's disease (HD) is fatal autosomal dominant neurodegenerative disorder. The exact causes of neuronal damage are unknown and effective treatment is not available. Basic research and clinical studies indicate that mitochondrial dysfunction plays an important role in the underlying mechanisms of striatal neuronal cell death both in HD patients and HD animal models. The data gained in this project will be directly applicable to developing novel therapeutic interventions in treating HD through the manipulation of the mitochondrial fission.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS088192-01
Application #
8744411
Study Section
Neural Oxidative Metabolism and Death Study Section (NOMD)
Program Officer
Sutherland, Margaret L
Project Start
2014-06-01
Project End
2019-05-31
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
1
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Case Western Reserve University
Department
Physiology
Type
Schools of Medicine
DUNS #
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Guo, Xing; Sun, XiaoYan; Hu, Di et al. (2016) VCP recruitment to mitochondria causes mitophagy impairment and neurodegeneration in models of Huntington's disease. Nat Commun 7:12646
Clinton, Ryan W; Francy, Christopher A; Ramachandran, Rajesh et al. (2016) Dynamin-related Protein 1 Oligomerization in Solution Impairs Functional Interactions with Membrane-anchored Mitochondrial Fission Factor. J Biol Chem 291:478-92
Macdonald, Patrick J; Francy, Christopher A; Stepanyants, Natalia et al. (2016) Distinct Splice Variants of Dynamin-related Protein 1 Differentially Utilize Mitochondrial Fission Factor as an Effector of Cooperative GTPase Activity. J Biol Chem 291:493-507
Filichia, Emily; Hoffer, Barry; Qi, Xin et al. (2016) Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson's disease model induced by MPTP. Sci Rep 6:32656
Qi, Xin; Davis, Brandon; Chiang, Yung-Hsiao et al. (2016) Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model. J Neurochem 138:746-57
(2016) Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy 12:1-222
Disatnik, Marie-Hélène; Joshi, Amit U; Saw, Nay L et al. (2016) Potential biomarkers to follow the progression and treatment response of Huntington's disease. J Exp Med 213:2655-2669
Su, Yu-Chin; Guo, Xing; Qi, Xin (2015) Threonine 56 phosphorylation of Bcl-2 is required for LRRK2 G2019S-induced mitochondrial depolarization and autophagy. Biochim Biophys Acta 1852:12-21
Filichia, E; Shen, H; Zhou, X et al. (2015) Forebrain neuronal specific ablation of p53 gene provides protection in a cortical ischemic stroke model. Neuroscience 295:1-10
Luo, Yu; Hoffer, Alan; Hoffer, Barry et al. (2015) Mitochondria: A Therapeutic Target for Parkinson's Disease? Int J Mol Sci 16:20704-30

Showing the most recent 10 out of 12 publications